

Diagnostik und Therapie von Dyslipidämien – mehr als LDL-Cholesterol-Senkung?

Literatur

- [1] Laufs, U, Weingartner, O, Kassner, U, et al. State of the Art: Therapie mit Statinen. Dtsch Med Wochenschr 2022;147:62-68.10.1055/a-1516-2471
- [2] Hegele, RA, Ginsberg, HN, Chapman, MJ, et al. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol 2014;2:655-66.10.1016/S2213-8587(13)70191-8
- [3] Nordestgaard, BG. Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology. Circ Res 2016;118:547-63.10.1161/CIRCRESAHA.115.306249
- [4] Aberra, T, Peterson, ED, Pagidipati, NJ, et al. The association between triglycerides and incident cardiovascular disease: What is „optimal“? J Clin Lipidol 2020;14:438-47 e3.10.1016/j.jacl.2020.04.009
- [5] Scholz, M, Tselmin, S, Fischer, S, et al. Hypertriglyceridemia in an outpatient department - Significance as an atherosclerotic risk factor. Atheroscler. Suppl 2015;18:146-53. doi: 10.1016/j.atherosclerosissup.2015.02.011.:146-53
- [6] Brunner, FJ, Waldeyer, C, Ojeda, F, et al. Application of non-HDL cholesterol for population-based cardiovascular risk stratification: results from the Multinational Cardiovascular Risk Consortium. Lancet 2019;394:2173-83.10.1016/S0140-6736(19)32519-X
- [7] Julius, U. Herkömmliche und zukünftige Therapiekonzepte bei Hypertriglyzeridämie. Nieren- und Hochdruckkrankheiten 2019;48:391-99
- [8] Keech, A, Simes, RJ, Barter, P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-61.10.1016/S0140-6736(05)67667-2
- [9] Elam, M, Lovato, L, Ginsberg, H. The ACCORD-Lipid study: implications for treatment of dyslipidemia in Type 2 diabetes mellitus. Clin Lipidol 2011;6:9-20.10.2217/clp.10.84
- [10] Mach, F, Baigent, C, Catapano, AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2019;41:111 - 88.10.1093/eurheartj/ehz455
- [11] Moulin, P, Dufour, R, Averna, M, et al. Characterisation of patients with familial chylomicronaemia syndrome (FCS) and multifactorial chylomicronaemia syndrome (MCS): Establishment of an FCS clinical diagnostic score. Data Brief 2018;21:1334-36.10.1016/j.dib.2018.10.125
- [12] Witztum, JL, Gaudet, D, Freedman, SD, et al. Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome. N Engl J Med 2019;381:531-42.10.1056/NEJMoa1715944
- [13] Dewey, FE, Gusarova, V, Dunbar, RL, et al. Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease. N Engl J Med 2017;377:211-21.10.1056/NEJMoa1612790

- [14] Tsimikas, S. A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies. *J Am Coll Cardiol* 2017;69:692-711.10.1016/j.jacc.2016.11.042
- [15] Reyes-Soffer, G, Ginsberg, HN, Berglund, L, et al. Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association. *Arterioscler Thromb Vasc Biol* 2022;42:e48-e60.10.1161/ATV.000000000000147
- [16] Fischer, S, Schatz, U, Julius, U, et al. Bedeutung der Lp(a)-Spiegel: zwei Kasuistiken – Patienten mit Hypercholesterinämie, massiv erhöhtem Lipoprotein(a)-Spiegel und schweren Gefäßkomplikationen. *Ärzteblatt Sachsen* 2019;23 – 26
- [17] Fischer, S, Julius, U, Tselmin, S, et al. [Lipoprotein(a): a risk factor for atherosclerosis]. *Dtsch. Med. Wochenschr* 2014;139:1204-06.10.1055/s-0034-1370011 [doi]
- [18] Julius, U, Tselmin, S, Schatz, U, et al. Lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 inhibitors. *Clin Res Cardiol Suppl* 2019;14:45-50.10.1007/s11789-019-00099-z
- [19] Bundesministerium für Gesundheit. Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Richtlinie Methoden vertragsärztliche Versorgung: Apherese bei isolierter Lp(a)-Erhöhung. *BAnz* 2008;138:3321
- [20] Julius, U, Tselmin, S, Schatz, U, et al. Actual situation of Lipoprotein apheresis in patients with elevated Lipoprotein(a) levels. *Atheroscler Suppl* 2019;40:1-7
- [21] Julius, U, Tselmin, S, Schatz, U, et al. Indikation und Ergebnisse der Apherese-Behandlung bei Lipoprotein(a)-Erhöhungen. *CardioVasc* 2019;19:35-38
- [22] Leebmann, J, Roeseler, E, Julius, U, et al. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study. *Circulation* 2013;128:2567-76.CIRCULATIONAHA.113.002432 [pii];10.1161/CIRCULATIONAHA.113.002432 [doi]
- [23] Roeseler, E, Julius, U, Heigl, F, et al. Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular Disease: Prospective 5 Years of Follow-Up and Apolipoprotein(a) Characterization. *Arterioscler Thromb Vasc Biol* 2016;36:2019-27.10.1161/ATVBAHA.116.307983
- [24] Schettler, V, Bernhardt, W, van Buuren, F, et al. Deutsches Lipoproteinapherese-Register - Jahresbericht 2020. In, 2021:1-101
- [25] Tsimikas, S, Karwatowska-Prokopczuk, E, Gouni-Berthold, I, et al. Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. *N Engl J Med* 2020;382:244-55.10.1056/NEJMoa1905239
- [26] Swerdlow, DI, Rider, DA, Yavari, A, et al. Treatment and prevention of lipoprotein(a)-mediated cardiovascular disease: the emerging potential of RNA interference therapeutics. *Cardiovasc Res* 2022;118:1218-31.10.1093/cvr/cvab100